[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-hepatic-porphyria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-hepatic-porphyria":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100430348","elevate-a-registry-of-patients-with-acute-hepatic-porphyria-ahp-100430348",false,"NCT04883905","ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)","ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)","ELEVATE","Inclusion Criteria:\n\n* Documented diagnosis of AHP, per physician's determination\n\nExclusion Criteria:\n\n* Currently enrolled in a clinical trial for any investigational agent","ALL","12 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.",[25],"Acute Hepatic Porphyria",[27,28,29],"Givosiran","AHP","Acute hepatic porphyria","RECRUITING","2026-04-23",{"date":33,"type":34},"2026-04-27","ACTUAL",{"date":36,"type":34},"2021-04-26",{"date":38,"type":21},"2027-04-01",{"name":40,"class":41},"Alnylam Pharmaceuticals","INDUSTRY",30]